Persistence After Switching From Adalimumab Biosimilar MSB11022 to Adalimumab Biosimilar GP2017 in Patients With Chronic Inflammatory Rheumatic Diseases

Objective: Provide real-world data on switching from adalimumab biosimilar MSB11022 to GP2017 related to persistence, adherence, and safety in adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). Methods: Retrospective cohort study that used...

Descripción completa

Detalles Bibliográficos
Autores: Borrás-Blasco, J, Valcuende-Rosique, A, Cornejo, S, Aparicio-Rubio, C, Aguilar-Zamora, M, Garijo-Bufort, M, Arévalo-Ruales, KR
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p18259
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/18259
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85212821223&doi=10.1177%2f87551225241306675&partnerID=40&md5=ddf20814e92501b3ba4dd678d138e90a
Access Level:acceso abierto
Palabra clave:persistence
adalimumab
real world
biosimilar
switching
id ES_65319383b2ef7c8e9cd7c20cd7c02adf
oai_identifier_str oai:fisabio.fundanetsuite.com:p18259
network_acronym_str ES
network_name_str España
repository_id_str
spelling Persistence After Switching From Adalimumab Biosimilar MSB11022 to Adalimumab Biosimilar GP2017 in Patients With Chronic Inflammatory Rheumatic DiseasesBorrás-Blasco, JValcuende-Rosique, ACornejo, SAparicio-Rubio, CAguilar-Zamora, MGarijo-Bufort, MArévalo-Ruales, KRpersistenceadalimumabreal worldbiosimilarswitchingObjective: Provide real-world data on switching from adalimumab biosimilar MSB11022 to GP2017 related to persistence, adherence, and safety in adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). Methods: Retrospective cohort study that used registries and medical records from a single hospital (June 2022 to April 2024). Adult patients with RA, PsA, and axSpA treated with adalimumab biosimilar MSB11022 who switched to biosimilar GP2017 were identified and followed up until April 2024, or disenrollment. Baseline demographic and clinical characteristics studied included sex, age, diagnosis, and previous treatment. Adherence was measured using medication possession ratio (MPR); patients with MPR >= 85% were considered adherent. Persistence, cause of discontinuation, safety, and dosage regimen were collected. Results: A total of 63 patients with chronic inflammatory rheumatic diseases, of whom 36 (57.1%) were women, with an average age of 53.9 years were included. In total, 24 had axSpA, 21 had RA, and 18 had PsA. A total of 58 patients (92.1%) were biologic-na & iuml;ve, and 27 (42.3%) received methotrexate. A total of 63 patients switched from adalimumab biosimilar MSB11022 to GP2017. After 12 months, 53 (84.1%) continued; 9 (14.3%) discontinued due to lack of effectiveness, side effects, or change of health department. The total persistence of patients who switched from MSB11022 to GP2017 was 12.4 +/- 3.1 months. Non-na & iuml;ve patients had a persistence of 13.7 +/- 0.5 months, and na & iuml;ve patients had 9.5 +/- 3.0 months, with no significant differences. The retention rate at 12 months was 84%, with an adherence rate of 88.2%. Conclusions: Switching from adalimumab biosimilar MSB11022 to biosimilar GP2017 in patients with chronic inflammatory rheumatic diseases did not lead to signs of safety or loss of efficacy over 12 months other than those already known in the literature for the class of drugs.SAGE PUBLICATIONS INC2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/18259https://www.scopus.com/inward/record.uri?eid=2-s2.0-85212821223&doi=10.1177%2f87551225241306675&partnerID=40&md5=ddf20814e92501b3ba4dd678d138e90aJOURNAL OF PHARMACY TECHNOLOGYISSN: 87551225ISSNe: 15494810reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p182592026-06-11T12:45:17Z
dc.title.none.fl_str_mv Persistence After Switching From Adalimumab Biosimilar MSB11022 to Adalimumab Biosimilar GP2017 in Patients With Chronic Inflammatory Rheumatic Diseases
title Persistence After Switching From Adalimumab Biosimilar MSB11022 to Adalimumab Biosimilar GP2017 in Patients With Chronic Inflammatory Rheumatic Diseases
spellingShingle Persistence After Switching From Adalimumab Biosimilar MSB11022 to Adalimumab Biosimilar GP2017 in Patients With Chronic Inflammatory Rheumatic Diseases
Borrás-Blasco, J
persistence
adalimumab
real world
biosimilar
switching
title_short Persistence After Switching From Adalimumab Biosimilar MSB11022 to Adalimumab Biosimilar GP2017 in Patients With Chronic Inflammatory Rheumatic Diseases
title_full Persistence After Switching From Adalimumab Biosimilar MSB11022 to Adalimumab Biosimilar GP2017 in Patients With Chronic Inflammatory Rheumatic Diseases
title_fullStr Persistence After Switching From Adalimumab Biosimilar MSB11022 to Adalimumab Biosimilar GP2017 in Patients With Chronic Inflammatory Rheumatic Diseases
title_full_unstemmed Persistence After Switching From Adalimumab Biosimilar MSB11022 to Adalimumab Biosimilar GP2017 in Patients With Chronic Inflammatory Rheumatic Diseases
title_sort Persistence After Switching From Adalimumab Biosimilar MSB11022 to Adalimumab Biosimilar GP2017 in Patients With Chronic Inflammatory Rheumatic Diseases
dc.creator.none.fl_str_mv Borrás-Blasco, J
Valcuende-Rosique, A
Cornejo, S
Aparicio-Rubio, C
Aguilar-Zamora, M
Garijo-Bufort, M
Arévalo-Ruales, KR
author Borrás-Blasco, J
author_facet Borrás-Blasco, J
Valcuende-Rosique, A
Cornejo, S
Aparicio-Rubio, C
Aguilar-Zamora, M
Garijo-Bufort, M
Arévalo-Ruales, KR
author_role author
author2 Valcuende-Rosique, A
Cornejo, S
Aparicio-Rubio, C
Aguilar-Zamora, M
Garijo-Bufort, M
Arévalo-Ruales, KR
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv persistence
adalimumab
real world
biosimilar
switching
topic persistence
adalimumab
real world
biosimilar
switching
description Objective: Provide real-world data on switching from adalimumab biosimilar MSB11022 to GP2017 related to persistence, adherence, and safety in adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). Methods: Retrospective cohort study that used registries and medical records from a single hospital (June 2022 to April 2024). Adult patients with RA, PsA, and axSpA treated with adalimumab biosimilar MSB11022 who switched to biosimilar GP2017 were identified and followed up until April 2024, or disenrollment. Baseline demographic and clinical characteristics studied included sex, age, diagnosis, and previous treatment. Adherence was measured using medication possession ratio (MPR); patients with MPR >= 85% were considered adherent. Persistence, cause of discontinuation, safety, and dosage regimen were collected. Results: A total of 63 patients with chronic inflammatory rheumatic diseases, of whom 36 (57.1%) were women, with an average age of 53.9 years were included. In total, 24 had axSpA, 21 had RA, and 18 had PsA. A total of 58 patients (92.1%) were biologic-na & iuml;ve, and 27 (42.3%) received methotrexate. A total of 63 patients switched from adalimumab biosimilar MSB11022 to GP2017. After 12 months, 53 (84.1%) continued; 9 (14.3%) discontinued due to lack of effectiveness, side effects, or change of health department. The total persistence of patients who switched from MSB11022 to GP2017 was 12.4 +/- 3.1 months. Non-na & iuml;ve patients had a persistence of 13.7 +/- 0.5 months, and na & iuml;ve patients had 9.5 +/- 3.0 months, with no significant differences. The retention rate at 12 months was 84%, with an adherence rate of 88.2%. Conclusions: Switching from adalimumab biosimilar MSB11022 to biosimilar GP2017 in patients with chronic inflammatory rheumatic diseases did not lead to signs of safety or loss of efficacy over 12 months other than those already known in the literature for the class of drugs.
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/18259
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85212821223&doi=10.1177%2f87551225241306675&partnerID=40&md5=ddf20814e92501b3ba4dd678d138e90a
url https://fisabio.portalinvestigacion.com/publicaciones/18259
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85212821223&doi=10.1177%2f87551225241306675&partnerID=40&md5=ddf20814e92501b3ba4dd678d138e90a
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SAGE PUBLICATIONS INC
publisher.none.fl_str_mv SAGE PUBLICATIONS INC
dc.source.none.fl_str_mv JOURNAL OF PHARMACY TECHNOLOGY
ISSN: 87551225
ISSNe: 15494810
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869409724186755072
score 15,811543

Similares en LA Referencia